

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                        |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/PTO<br><br><h1>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</h1><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|   |   |    |   | Application Number       | 09/402,820-Conf. #6495 |
|   |   |    |   | Filing Date              | October 12, 1999       |
|   |   |    |   | First Named Inventor     | Daniel G. Chain        |
|   |   |    |   | Art Unit                 | 1645                   |
|   |   |    |   | Examiner Name            | P. A. Duffy            |
|   |   |    |   | Attorney/Docket Number   | 20555/1203301-US1      |
| Sheet   | 1 | of | 2 |                          |                        |

[illegible][illegible]

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 09/402,820-Conf. #6495 |
|  |   |    |   | Filing Date              | October 12, 1999       |
|  |   |    |   | First Named Inventor     | Daniel G. Chain        |
|  |   |    |   | Art Unit                 | 1645                   |
|  |   |    |   | Examiner Name            | P. A. Duffy            |
| Sheet  | 2 | of | 2 | Attorney Docket Number   | 20555/1203301-US1      |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials            | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 | CA                       | SOLOMON, B., Immunological Concepts in the Treatment of Alzheimer's Disease, <i>Drug Dev. Res.</i> 56:163-167 (2002)  |                |
|                                 | CB                       | SOLOMON, B., Immunotherapeutic Strategies for Prevention and Treatment of Alzheimer's Disease, <i>DNA and Cell Biol.</i> 20:697-703 (2001)  |                |
|                                 | CC                       | FRENKEL et al., N-terminal EFRH of Alzheimer's $\beta$ -amyloid Peptide Represents the Epitope of its Anti-aggregating Antibodies, <i>J. Neuroimmunol.</i> 88:85-90 (1998).   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.